OH-2是一种无IGH易位的超二倍体骨髓瘤细胞系，有一个复杂易位，使MYC在MAFB和IGK基因座附近并列。
OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus.
作者信息
Våtsveen Thea Kristin, Tian Erming, Kresse Stine H, Meza-Zepeda Leonardo A, Gabrea Ana, Glebov Oleg, Dai Hong Yan, Sundan Anders, Kuehl W Michael, Børset Magne
机构信息
Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
出版信息
Leuk Res. 2009 Dec;33(12):1670-7. doi: 10.1016/j.leukres.2009.03.001. Epub 2009 Apr 23.
Abstract
Multiple myeloma can be classified into hyperdiploid (HRD) (with 48-74 chromosomes) and non-hyperdiploid tumors (usually with immunoglobulin heavy chain translocations). The OH-2 human myeloma cell line (HMCL) retains the same HRD genotype as the primary tumor, with extra copies of chromosomes 3, 7, 15, 19, and 21. Both OH-2 and primary cells have a complex secondary translocation in which the IGK 3' enhancer is inserted between MYC and MAFB, resulting in dysregulation of both oncogenes. OH-2 provides a unique example of an HMCL and the corresponding primary tumor that are shown to share the same HRD genotype.
摘要
多发性骨髓瘤可分为超二倍体（HRD）（有48 - 74条染色体）和非超二倍体肿瘤（通常有免疫球蛋白重链易位）。OH - 2人骨髓瘤细胞系（HMCL）保留了与原发性肿瘤相同的HRD基因型，有额外的3、7、15、19和21号染色体拷贝。OH - 2细胞和原发性细胞都有一个复杂的继发性易位，其中IGK 3'增强子插入到MYC和MAFB之间，导致两个癌基因的失调。OH - 2提供了一个独特的例子，即一个HMCL和相应的原发性肿瘤被证明具有相同的HRD基因型。
相似文献
1
OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus.
Leuk Res. 2009 Dec;33(12):1670-7. doi: 10.1016/j.leukres.2009.03.001. Epub 2009 Apr 23.
2
Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.
Genes Chromosomes Cancer. 2008 Jul;47(7):573-90. doi: 10.1002/gcc.20563.
3
Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype.
Leukemia. 2013 Apr;27(4):925-31. doi: 10.1038/leu.2012.302. Epub 2012 Oct 22.
4
Novel three-break rearrangement and cryptic translocations leading to colocalization of MYC and IGH signals in B-cell acute lymphoblastic leukemia.
Cancer Genet Cytogenet. 2006 Mar;165(2):180-4. doi: 10.1016/j.cancergencyto.2005.08.015.
5
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.
Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):228-33. doi: 10.1073/pnas.97.1.228.
6
High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization.
Genes Chromosomes Cancer. 1999 Jan;24(1):9-15. doi: 10.1002/(sici)1098-2264(199901)24:1<9::aid-gcc2>3.0.co;2-k.
7
Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations.
Jpn J Cancer Res. 2001 Jun;92(6):638-44. doi: 10.1111/j.1349-7006.2001.tb01142.x.
8
High prevalence of immunoglobulin light chain gene aberrations as revealed by FISH in multiple myeloma and MGUS.
Genes Chromosomes Cancer. 2014 Aug;53(8):650-6. doi: 10.1002/gcc.22175. Epub 2014 Apr 12.
9
Complex IGH rearrangements in multiple myeloma: Frequent detection discrepancies among three different probe sets.
Genes Chromosomes Cancer. 2014 Jun;53(6):467-74. doi: 10.1002/gcc.22158. Epub 2014 Mar 3.
10
Establishment and characterization of a new human myeloma cell line, KYdelta-1, producing the delta/kappa type immunoglobulin.
Cancer Genet Cytogenet. 2001 Oct 1;130(1):42-50. doi: 10.1016/s0165-4608(01)00467-8.
引用本文的文献
1
Targeting proteostasis in multiple myeloma through inhibition of LTK.
Leukemia. 2025 Jul 9. doi: 10.1038/s41375-025-02682-8.
2
Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy.
Sci Rep. 2024 Nov 20;14(1):28805. doi: 10.1038/s41598-024-80263-y.
3
The pro-tumorigenic cytokine IL-32 has a high turnover in multiple myeloma cells due to proteolysis regulated by oxygen-sensing cysteine dioxygenase and deubiquitinating enzymes.
Front Oncol. 2023 May 29;13:1197542. doi: 10.3389/fonc.2023.1197542. eCollection 2023.
4
Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma.
Cancers (Basel). 2023 Apr 19;15(8):2373. doi: 10.3390/cancers15082373.
5
IL-32 is induced by activation of toll-like receptors in multiple myeloma cells.
Front Immunol. 2023 Feb 16;14:1107844. doi: 10.3389/fimmu.2023.1107844. eCollection 2023.
6
Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines.
Front Oncol. 2022 Nov 29;12:1040730. doi: 10.3389/fonc.2022.1040730. eCollection 2022.
7
MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.
BMC Cancer. 2018 Jul 6;18(1):724. doi: 10.1186/s12885-018-4602-4.
8
Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia.
Oncotarget. 2017 Mar 21;8(12):19427-19442. doi: 10.18632/oncotarget.14294.
9
Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells.
Blood Cancer J. 2016 Jul 15;6(7):e446. doi: 10.1038/bcj.2016.56.
10
Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.
J Transl Med. 2016 Mar 15;14:71. doi: 10.1186/s12967-016-0830-z.
本文引用的文献
1
Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.
Genes Chromosomes Cancer. 2008 Jul;47(7):573-90. doi: 10.1002/gcc.20563.
2
Genetic aberrations and survival in plasma cell leukemia.
Leukemia. 2008 May;22(5):1044-52. doi: 10.1038/leu.2008.4. Epub 2008 Jan 24.
3
Genetic events in the pathogenesis of multiple myeloma.
Best Pract Res Clin Haematol. 2007 Dec;20(4):571-96. doi: 10.1016/j.beha.2007.08.004.
4
Cell lines of hyperdiploid myeloma, are we there yet?
Br J Haematol. 2008 Mar;140(5):579-80; author reply 580-1. doi: 10.1111/j.1365-2141.2007.06905.x. Epub 2007 Nov 19.
5
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.
Blood. 2008 Jan 15;111(2):806-15. doi: 10.1182/blood-2007-07-101139. Epub 2007 Oct 12.
6
Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines.
Br J Haematol. 2007 Sep;138(6):802-11. doi: 10.1111/j.1365-2141.2007.06742.x.
7
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.
Cancer Res. 2007 Apr 1;67(7):2982-9. doi: 10.1158/0008-5472.CAN-06-4046.
8
Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression.
Cell Div. 2006 Oct 18;1:23. doi: 10.1186/1747-1028-1-23.
9
Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas.
Cancer Res. 2006 Sep 15;66(18):8984-93. doi: 10.1158/0008-5472.CAN-06-1972.
10
The molecular classification of multiple myeloma.
Blood. 2006 Sep 15;108(6):2020-8. doi: 10.1182/blood-2005-11-013458. Epub 2006 May 25.
Zotero 插件